The trial is taking place at:
C

Clinica Universidad de Navarra | Sede Madrid - Hematology Department

Veeva-enabled site

A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors

F

Famewave

Status and phase

Active, not recruiting
Phase 2
Phase 1

Conditions

Solid Tumor
Colorectal Adenocarcinoma
Melanoma
Papillary Thyroid Cancer
Non Small Cell Lung Cancer
Ovarian Cancer
Pancreatic Cancer

Treatments

Drug: CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
Drug: CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion
Drug: Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
Drug: Nivolumab and Nal-IRI/5-FU/LV - Expansion
Drug: CM-24 and Nivolumab - Dose Escalation

Study type

Interventional

Funder types

Industry

Identifiers

NCT04731467
FW-2020-1

Details and patient eligibility

About

This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advanced metastatic pancreatic cancer (Parts C \& D) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV will be administered subsequent to CM24 and nivolumab. CM24, nivolumab and gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV are administered intravenously.

Enrollment

79 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

1. Part A: Previously treated subjects with recurrent and/or metastatic NSCLC, pancreatic cancer, ovarian cancer, papillary thyroid cancer, colorectal adenocarcinoma and melanoma with documented progression/intolerance following at least one previous therapy (and not more than 2 previous regimens); Part C: Subjects with histologically confirmed advanced metastatic pancreatic adenocarcinoma as defined by NCCN Guidelines; Subjects with islet cell neoplasms are excluded; subjects with a maximum of 1 prior treatment regimen for metastatic disease excluding: nab-paclitaxel containing regimens and up to 8 weeks from last chemotherapy treatment (Arm #1); fluoropyrimidine or irinotecan containing regimens and up to 8 weeks from last chemotherapy treatment (Arm #2). Part C, D: Subjects with histologically confirmed advanced metastatic pancreatic adenocarcinoma as defined by NCCN Guidelines; Subjects with islet cell neoplasms are excluded. 2. Parts C, D: Subjects who have progressed on or after standard of care chemotherapy with a maximum of 1 prior treatment regimen for advanced metastatic disease: * Subjects enrolled in arm with gemcitabine/nab-paclitaxel combination should have received a fluoropyrimidine and/or irinotecan containing regimen in the first line of treatment; Prior gemcitabine containing regimen may be allowed only if completed at least 6 months prior to study enrollment. * Arm #2: Subjects enrolled in arm with Nal-IRI/5FU/LV combination should have received a gemcitabine and/or nab-paclitaxel containing regimen in the first line of treatment; Prior irinotecan and/or fluoropyrimidine containing regimens may be allowed only if completed at least 6 months prior to study enrollment. 3. Part A: Availability of an archival tumor sample prior to first treatment. Parts C, D: Fresh tumor biopsy must be obtained within 3 months prior to enrollment and after the last systemic treatment was completed. 4. Must have at least 1 measurable lesion per RECIST1.1 with progressing or new tumors since last antitumor therapy; 5. ECOG performance status score of 0 or 1; 6. Adequate safety lab results; 7. Stable brain metastases; 8. WCBP (Women of Childbearing Potential) must have a negative serum pregnancy test at Screening and a negative urine pregnancy test, WCBP must agree to abstain from sex or use an adequate method of contraception, males must abstain from sex with WCBP or use an adequate method of contraception.

Exclusion criteria

1. Part A: Received more than two prior systemic regimens for the metastatic disease Parts C and D: Received more than 1 prior systemic regimens for the advanced metastatic disease 2. Part A: History of weight loss \>10% over the 2 months prior to Screening; 3. Unresolved AEs \> Grade 1 from prior anticancer therapy. 4. Concurrent malignancy requiring treatment; 5. Active, untreated central nervous system (CNS) metastases; 6. Subjects previously treated with an anti PD-1/PD-L1 targeting agent with history immune mediated toxicity; 7. Severely immunocompromised; 8. History of allergy or hypersensitivity to any of the study treatment components; 9. Major surgery within 4 weeks of study administration; 10. Received a live / attenuated vaccine within 30 days of first treatment 11. Clinically relevant serious co-morbid medical conditions including, but not limited to: * Active infection; * Recent (within six months of Screening) cardiac disease, myocardial infarction, or severe or unstable angina; * History of serious arrhythmia; * Chronic obstructive or chronic restrictive pulmonary disease, pulmonary hypertension history of or active interstitial lung disease or pneumonitis; * Prior organ allograft; * Subjects with active, known or suspected autoimmune disease; * History of active or latent tuberculosis infection; * Positive test for HIV, HBV, or HCV; 12. Radiation within two weeks prior to the first study treatment; 13. Treatment with another investigational therapy within 30 days or 5 half-lives of the drug prior to Screening, whichever is longer; 14. Treatment with botanical preparations (e.g., herbal supplements or traditional Chinese medicines) intended for general health support or to treat the disease under study within 2 weeks prior to treatment; 15. Pregnant or lactating women.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

79 participants in 7 patient groups

Part A- Dose escalation of CM24 in combination with nivolumab
Experimental group
Treatment:
Drug: CM-24 and Nivolumab - Dose Escalation
Part C- Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine
Experimental group
Treatment:
Drug: CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
Part C- Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV
Experimental group
Treatment:
Drug: CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion
Part D- Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine
Experimental group
Treatment:
Drug: CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
Part D- Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV
Experimental group
Treatment:
Drug: CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion
Part D- Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine
Active Comparator group
Treatment:
Drug: Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
Part D- Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV
Active Comparator group
Treatment:
Drug: Nivolumab and Nal-IRI/5-FU/LV - Expansion

Trial contacts and locations

18

Loading...

Central trial contact

Michael Schickler, PhD; Hadas Nachmanson

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems